Advance Search
XIE Shu, SHAO Hua, LIU Bin, WANG Zhen. Effect observation of dronedarone in the treatment of patients with paroxysmal atrial fibrillation[J]. Journal of Clinical Medicine in Practice, 2023, 27(7): 89-92. DOI: 10.7619/jcmp.20223669
Citation: XIE Shu, SHAO Hua, LIU Bin, WANG Zhen. Effect observation of dronedarone in the treatment of patients with paroxysmal atrial fibrillation[J]. Journal of Clinical Medicine in Practice, 2023, 27(7): 89-92. DOI: 10.7619/jcmp.20223669
shu

Effect observation of dronedarone in the treatment of patients with paroxysmal atrial fibrillation

  • 1.

    Department of Cardiology, Yangzhou Friendship Hospital of Jiangsu Province, Yangzhou, Jiangsu, 225000

  • 2.

    Medical College of Yangzhou University, Yangzhou, Jiangsu, 225000

More Information
  • Received Date: December 07, 2022
  • Revised Date: December 21, 2022
  • Available Online: April 22, 2023
    Graphical Abstract
    • Abstract
  • Objective 

    To observe the efficacy and safety of dronedarone in the treatment of patients with paroxysmal atrial fibrillation.

    Methods 

    A total of 56 patients with paroxysmal atrial fibrillation were randomly divided into treatment group with 29 cases and control group with 27 cases. Patients in both groups were conducted with relevant assessments before enrollment, the contraindications to anticoagulation were also excluded, and then routine anticoagulation therapy was performed; the patients in the treatment group took dronedarone hydrochloride tablets orally for three consecutive months. Before and after treatment, number of times of atrial fibrillation attack, the maximum duration of a single atrial fibrillation attack, change of sinus resting heart rate, cardiac function indicators [left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVDd), left atrial diameter (LAD), N-terminal pro-B-type natriuretic peptide (NT-proBNP)]and adverse reactions were compared between two groups.

    Results 

    After treatment, the total number of times of atrial fibrillation attack and sinus resting heart rate in the treatment group decreased significantly when compared to those before treatment, and the longest duration of atrial fibrillation attack shortened significantly (P < 0.05); after treatment, the total number of times of atrial fibrillation attack and sinus resting heart rate in the treatment group were significantly lower than those in the control group, and the longest duration of atrial fibrillation attack was significantly shorter than that in the control group (P < 0.05). After treatment, LVEF in the treatment group increased significantly when compared to that before treatment, while LVDd, LAD and NT-proBNP decreased significantly when compared to those before treatment (P < 0.05); after treatment, LVEF in the treatment group was significantly higher than that in the control group, while LVDd, LAD and NT-proBNP were significantly lower than those in the control group (P < 0.05). After treatment, the incidence of adverse reactions in the control group was 7.41%, which showed no significant difference when compared to 6.90% in the treatment group (P>0.05).

    Conclusion 

    Dronedarone can effectively control the ventricular rate of patients with paroxysmal atrial fibrillation, shorten the duration of atrial fibrillation attack, reduce the frequency of atrial fibrillation attack, maintain sinus rhythm, improve cardiac function indicators, and cause less adverse reactions.

    • FullText(HTML)
    • References (12)
  • [1]
    SUN X R, HE S N, LIN Z Y, et al. Radiofrequency catheter ablation versus cryoballoon ablation in the treatment of paroxysmal atrial fibrillation: a cost-effectiveness analysis in China[J]. Clin Ther, 2019, 41(1): 78-91. doi: 10.1016/j.clinthera.2018.11.008
    [2]
    SBAROUNI E, KOGERAKIS N, STAVRIDIS G. 68-year-old woman with paroxysmal atrial fibrillation[J]. Heart, 2018: heartjnl-2018.
    [3]
    SOGA F, TANAKA H, MOCHIZUKI Y, et al. Combined assessment of left atrial volume parameters for predicting recurrence of atrial fibrillation following pulmonary vein isolation in patients with paroxysmal atrial fibrillation[J]. Echocardiography, 2019, 36(5): 862-869. doi: 10.1111/echo.14315
    [4]
    KRANERT M, SHCHETYNSKA-MARINOVA T, LIEBE V, et al. Recurrence of atrial fibrillation in dependence of left atrial volume index[J]. Vivo, 2020, 34(2): 889-896. doi: 10.21873/invivo.11854
    [5]
    MOHANTY S, DELLA ROCCA D G, GIANNI C, et al. Predictors of recurrent atrial fibrillation following catheter ablation[J]. Expert Rev Cardiovasc Ther, 2021, 19(3): 237-246. doi: 10.1080/14779072.2021.1892490
    [6]
    BODDUM K, SALJIC A, JESPERSEN T, et al. A novel SCN5A variant associated with abnormal repolarization, atrial fibrillation, and reversible cardiomyopathy[J]. Cardiology, 2018, 140(1): 8-13. doi: 10.1159/000487475
    [7]
    NATTEL S, GUASCH E, SAVELIEVA I, et al. Early management of atrial fibrillation to prevent cardiovascular complications[J]. Eur Heart J, 2014, 35(22): 1448-1456. doi: 10.1093/eurheartj/ehu028
    [8]
    VLACHOS K, LETSAS K P, KORANTZOPOULOS P, et al. Prediction of atrial fibrillation development and progression: current perspectives[J]. World J Cardiol, 2016, 8(3): 267. doi: 10.4330/wjc.v8.i3.267
    [9]
    JASON G, ANDRADE, MD C, et al. The 2020 Canadian cardiovascular society/Canadian heart rhythm society comprehensive guidelines for the management of atrial fibrillation[J]. Can J Cardiol, 2020, 36(12): 1847-1948. doi: 10.1016/j.cjca.2020.09.001
    [10]
    NATTEL S, DOBREV D. Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation[J]. Nat Rev Cardiol, 2016, 13(10): 575-590. doi: 10.1038/nrcardio.2016.118
    [11]
    JANUARY C T, WANN L S, CALKINS H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society[J]. Circulation, 2019, 140(6): e125-e151.
    [12]
    HEIJMAN J, HOHNLOSER S H, CAMM A J. Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future[J]. Europace, 2021, 23(Supplement_2): ii14-ii22. doi: 10.1093/europace/euaa426
    • Related Articles

  • Related Articles

    [1]HUANG Lingfang, DA Yingxiao, ZHOU Song, DI Ningning. Efficacy of vericiguat combined with recombinant human brain natriuretic peptide in the treatment of heart failure patients with low ejection fraction[J]. Journal of Clinical Medicine in Practice, 2024, 28(22): 67-70, 77. DOI: 10.7619/jcmp.20242475
    [2]TANG Yuanyuan, LI Hua. Clinical efficacy of Tongluo Yangxin Recipe combined with anti-hypertensive drugs in treating hypertension patients complicated with left ventricular diastolic dysfunction[J]. Journal of Clinical Medicine in Practice, 2024, 28(6): 94-98. DOI: 10.7619/jcmp.20240859
    [3]DAI Yonghui, CHEN Yong. Effect of hyperdynamic left ventricular ejection fraction on prognosis of early septic shock patients[J]. Journal of Clinical Medicine in Practice, 2022, 26(24): 76-80. DOI: 10.7619/jcmp.20222995
    [4]ZHANG Chao, DU Zongli, LI Zhenglan, SUN Yueyuan, XIE Xiaotong, HU Xuebing, CUI Mengmeng. Efficacy of Jiawei Shengxian Decoction combined with conventional treatment in patients with ejection fraction reserved heart failure[J]. Journal of Clinical Medicine in Practice, 2022, 26(10): 47-50, 67. DOI: 10.7619/jcmp.20215210
    [5]SHI Gang, ZHU Lin, ZHANG Yuhong, ZHAO Yong. Effect of Ginkgo Leaf Extract and Dipyridamole Injection on left ventricular ejection fraction and serum B-type natriuretic peptide in patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(18): 44-46. DOI: 10.7619/jcmp.202018012
    [6]ZHANG Suping, WANG Xuejie, ZHANG Jiang. Effects of tolvaptan combined with levosimendan in treating elderly patients with intractable heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(18): 41-43,53. DOI: 10.7619/jcmp.202018011
    [7]CHEN Zhixian, ZHU Zongcheng, SHENG Xiaodong. Efficacy analysis of rosuvastatin combined with ezetimibe in the treatment of patients with acute myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2020, 24(18): 26-29. DOI: 10.7619/jcmp.202018007
    [8]CHEN Gang. Correlation between resting heart rate and serum high sensitive C reactive protein, brain natriuretic peptide and left ventricular ejection fraction in patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2019, 23(24): 31-33, 36. DOI: 10.7619/jcmp.201924010
    [9]ZHANG Pei, ZHOU Guanlin. Effect of rehabilitation nursing pathway on short-term and long-term treatment efficacy of patients with acute myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2018, (4): 1-4. DOI: 10.7619/jcmp.201804001
    [10]QU Linnan, CUI Yufang, YU Bin. Effect of early rehabilitation on left ventricular ejection fraction and exercise tolerance in patients with acute myocardial infarction treated by radial artery PCI[J]. Journal of Clinical Medicine in Practice, 2017, (8): 5-7. DOI: 10.7619/jcmp.201708002

  • Cited by

    Periodical cited type(3)

    1. 张红霞，王雪彤，刘莉红. 决奈达隆联合利伐沙班治疗阵发性房颤的临床效果. 宁夏医学杂志. 2024(02): 151-153 .
    2. 王俊伟，杜利军，王旭，曾玲，申钊，侯博. 经食道超声心动图在卵圆孔未闭合并房颤患者左心耳容积和功能改变评估中的应用. 实用临床医药杂志. 2024(09): 20-24 . 本站查看
    3. 谭辉龙. 经食道超声引导下冷冻导管消融术治疗阵发性房颤的临床效果观察. 影像研究与医学应用. 2023(24): 188-190 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (215) PDF downloads (13) Cited by(3)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return